Abstract
Dr. Ronald Desrosiers of the New England Primate Research Center at the Harvard Medical School provides his opinions on the HIV-1deltakURNe vaccine strain. Dr. Desrosiers explains what this strain represents and how it was chosen for live-attenuated HIV vaccine human safety trials. Further, Desrosiers discusses the balance in using highly attenuated vaccines and protection effectiveness, whether it is possible for the vaccine strain to revert to a disease-causing form, the possibility of transmission of a vaccine virus to unvaccinated individuals, and the issue of cancer development through insertional mutagenesis.
Original language | English (US) |
---|---|
Pages (from-to) | 45-46 |
Number of pages | 2 |
Journal | Journal of the International Association of Physicians in AIDS Care |
Volume | 4 |
Issue number | 3 |
State | Published - Mar 1998 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)